Endo to cut 560 staffers, shutter drug plants to save cash for spring cellulite launch

After several tough years and a CEO switch earlier in 2020, Endo is overhauling its operations—and cutting hundreds of jobs—to better position itself for a drug launch next spring.

The company on Thursday unveiled a move to cut 560 positions by the first half of 2026 to save $85 million to $95 million annually. Meanwhile, it will exit manufacturing facilities in California and New York and jettison an active pharmaceutical ingredient site in India.